Pyrotinib-based therapeutic approaches for HER2-positive breast cancer: the time is now.

Qi, Xiaowei; Shi, Qiyun; Xuhong, Juncheng; Zhang, Yi; Jiang, Jun

Qi, Xiaowei; Shi, Qiyun; Xuhong, Juncheng; Zhang, Yi; Jiang, Jun.

Affiliation

Qi X; Department of Breast and Thyroid Surgery, Southwest Hospital, Army Medical University, Chongqing, 400038, China.
Shi Q; Department of Breast and Thyroid Surgery, Southwest Hospital, Army Medical University, Chongqing, 400038, China.
Xuhong J; The Eighth Medical Center of Chinese PLA General Hospital, Beijing, 100091, China.
Zhang Y; Department of Breast and Thyroid Surgery, Southwest Hospital, Army Medical University, Chongqing, 400038, China.
Jiang J; Shigatse Branch, Xinqiao Hospital, Army Medical University, Shigatse, 857000, China.

Breast Cancer Res ; 25(1): 113, 2023 10 03.

Article in En | MEDLINE | ID: mdl-37789330

Subject(s)

Breast Neoplasms; Humans; Female; Breast Neoplasms/drug therapy; Breast Neoplasms/genetics; Breast Neoplasms/metabolism; Receptor, ErbB-2/metabolism; Aminoquinolines/therapeutic use; Acrylamides/therapeutic use; Antibodies, Monoclonal

Key words

Breast cancer; HER-2 positive; Pyrotinib; Targeted therapy; Tyrosine-kinase inhibitor

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms Type of study: Prognostic_studies Limits: Female / Humans Language: En Journal: Breast Cancer Res Journal subject: NEOPLASIAS Year: 2023 Type: Article Affiliation country: China

Fulltext

XML

PubMed Links

Search on Google